Latest 10-Q quarterly reports

CalciMedica, Inc. announced its first quarter 2026 financial results, reporting a net income of $5.0 million, a significant turnaround from the prior year's net loss.

Immunome, Inc. reported its first-quarter 2026 financial results, highlighting continued investment in its oncology pipeline and a strong cash position.

Ark Restaurants Corp. experienced a revenue decline in its second fiscal quarter of 2026, impacted by ongoing litigation concerning its Bryant Park locations and a decrease in same-store sales across several regions.

Nkarta, Inc. filed its Q1 2026 Form 10-Q, detailing a net loss of $27.8 million and continued investment in its lead CAR NK cell therapy candidate, NKX019, for autoimmune diseases.

IZEA Worldwide's Q1 2026 results show a 18% revenue decrease year-over-year, attributed to a strategic pivot towards higher-margin enterprise clients.

iAnthus Capital Holdings reported a net loss of $14.3 million for the first quarter of 2026, with revenues decreasing by 11.6% year-over-year, primarily due to divestitures and competitive pressures in established markets.

TriSalus Life Sciences reports a net income of $1.539 million for Q1 2026, a significant turnaround from a net loss of $10.375 million in Q1 2025, driven by gains in fair value of financial instruments.

Kyverna Therapeutics reported a decrease in R&D expenses for Q1 2026, alongside progress in its clinical trials for autoimmune diseases.

Janus International Group reported a significant drop in net income for Q1 2026, largely due to increased costs and a decline in organic revenue, despite a boost from the Kiwi II acquisition.

Oklo Inc. reported a significant increase in cash and marketable securities to $2.54 billion, alongside a substantial rise in R&D expenses for the first quarter of 2026.

General Purpose Acquisition Corp. reports net income of $1.68 million for Q1 2026, primarily from trust account interest, while continuing its search for a business combination.

Revvity, Inc. announced its first-quarter fiscal year 2026 financial results, showing a 7% increase in total revenue to $711.1 million, while net income saw a slight decrease compared to the prior year.

Bolt Biotherapeutics reported a net loss of $7.2 million for Q1 2026, a decrease from the prior year, but highlighted substantial doubt about its ability to continue as a going concern.

Tenax Therapeutics reports a significant increase in R&D expenses for Q1 2026, driven by ongoing Phase 3 trials for levosimendan, while extending its cash runway into early 2028.

a.k.a. Brands Holding Corp. reported a 3% increase in net sales for Q1 2026, driven by higher order volumes, with a significant improvement in gross margin to 63%, though the company still posted a net loss.

Gouverneur Bancorp, Inc. reported a net income of $217,000 for the first quarter of 2026, a significant increase from $118,000 in the prior year period, driven by higher net interest income.

SilverBox Corp V reports a net income of $577,337 for the quarter ended March 31, 2026, driven by interest income from its trust account, while its trust account balance grew to over $279 million.

Relmada Therapeutics reports significant progress in its clinical pipeline with NDV-01 and sepranolone, bolstered by a substantial capital raise, while navigating operational expenses.

Kyntra Bio, Inc. (KYNB) filed its Q1 2026 10-Q, detailing a net loss from continuing operations and strategic updates on its oncology and rare disease pipeline, including FG-3246 and roxadustat.

PepGen Inc. reported a net loss of $17.8 million for Q1 2026, with a significant decrease in R&D expenses and a cash runway extending into the second half of 2027.

Savara Inc. reported a wider net loss in Q1 2026 due to increased R&D and G&A expenses, alongside an FDA review extension for MOLBREEVI.

Fractyl Health reports a significant swing to net income in Q1 2026, driven by favorable changes in warrant liabilities, despite a decrease in research and development expenses.

Palisade Bio, Inc. filed its Q1 2026 10-Q report, detailing a net loss of $9.6 million and significant increases in R&D and G&A expenses, while highlighting positive clinical trial results for its lead candidate, PALI-2108.

Opus Genetics reports a significant increase in R&D expenses for its inherited retinal disease pipeline, alongside a substantial swing in warrant liability fair value, impacting net loss for the first quarter of 2026.

Vyome Holdings, Inc. filed its Q1 2026 10-Q, detailing a significant increase in R&D expenses and a new exclusive license agreement for JAK inhibitor assets.

Sanara MedTech Inc. announced a 19% increase in net revenue for Q1 2026, driven by strong performance in soft tissue repair products, and achieved net income from continuing operations.

Ambiq Micro's Q1 2026 results show a 59.3% surge in net sales driven by new product launches and increased customer demand, though net loss widened.

Solid Biosciences reported a wider net loss in Q1 2026 due to increased R&D investments, but maintained a robust cash position and advanced its gene therapy pipeline.

Interface Inc. reported a significant increase in net sales and net income for the first quarter of 2026, driven by higher sales volume and improved gross profit margins.

Espey Mfg. & Electronics Corp. reports a significant increase in net income and gross profit for the third quarter of fiscal year 2026, driven by improved product mix and operational efficiencies.